Skip to main content
SpringerLink
Log in
Book cover

Sports Cardiology Essentials pp 371–385Cite as

Cardiac Effects of Ergogenic Aides and Supplements

  • Chapter
  • First Online:

  • 1325 Accesses

Abstract

Great concern exists that athletes who regularly exercise are using dietary supplements and other purported ergogenic aids as a means for enhancing athletic performance and altering body composition.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Herbal treatments: the promises and pitfalls. Consum Rep. 1999;64:44–48.

    Google Scholar 

  2. Green GA, Uryasz FD, Petr TA, et al. NCAA study of substance use and abuse habits of college student-athletes. Clin J Sport Med. 2001;11:51–56.

    Article  PubMed  CAS  Google Scholar 

  3. IOC Press release. 4 April, 2002; http://www.olympic.or/uk/news/publications/press_ik.asp?release=266.

  4. Deligiannis A, Bjöornstad H, Carre F, et al. ESC Study Group of Sports Cardiology. ESC Study Group of Sports Cardiology Position Paper on adverse cardiovascular effects of doping in athletes. Eur J Cardiovasc Prev Rehabil. 2006;13:687–694.

    Article  PubMed  Google Scholar 

  5. Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc. 1995;27:1252–1262.

    PubMed  CAS  Google Scholar 

  6. Kerr JM, Congeni JA. Anabolic-androgenic steroids: use and abuse in pediatric patients. Pediatr Clin N Am. 2007;54:771–785.

    Article  Google Scholar 

  7. Sadler MA, Griffiths KA, McCredie RJ, et al. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol. 2001;37:224–230.

    Article  Google Scholar 

  8. Hickson RC, Ball KL, Falduto MT. Adverse effects of anabolic steroids. Med Toxicol Adverse Drug Exp. 1989;4:254–271.

    Article  PubMed  CAS  Google Scholar 

  9. Glazer G. Arthogenic effects of anabolic steroids on serum lipid levels. Arch Intern Med. 1991;151:1925–1933.

    Article  PubMed  CAS  Google Scholar 

  10. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34:513–554.

    Article  PubMed  Google Scholar 

  11. National Institute on Drug Abuse Research Report – Steroid Abuse and Addiction. National Institutes of Health Education Publication No. 00–3721. Bethesda (MD): National Institutes of Health; 2000.

    Google Scholar 

  12. Hartgens F, Reitjens G, Keizer HA, et al. Effects of androgenic-anabolic steroids on apolipoprotiesn and lipoproteins (a). Br J Sports Med. 2004;38:253–259.

    Article  PubMed  CAS  Google Scholar 

  13. Sullivan ML, Martinez CM, Gennis P, et al. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998;41:1–15.

    Article  PubMed  CAS  Google Scholar 

  14. Riebe D, Fernhall B, Thompson PD. The blood pressure response to exercise in anabolic steroid users. Med Sci Sports Exerc. 1992;24:633–637.

    PubMed  CAS  Google Scholar 

  15. McKillop G, Todd IC, Ballantine D. Increased left ventricular mass in a bodybuilder using anabolic steroids. Br J Sports Med. 1986;20:151–152.

    Article  PubMed  CAS  Google Scholar 

  16. Urhausen A, Holpes R, Kindermann W. One and two-dimensional echocardiography in body builders using anabolic steroids. Eur J Appl Physiol. 1989;58:633–640.

    Article  CAS  Google Scholar 

  17. Sullivan M, Martinez C, Gallagher J. Atrial fibrillation and anabolic steroids. J Emerg Med. 1999;17(5):851–857.

    Article  PubMed  CAS  Google Scholar 

  18. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart. 2004;90(5):496–501.

    Article  PubMed  CAS  Google Scholar 

  19. Clark BM, Schofield RS. Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. Pharmacotherapy. 2005;25(5):756–761.

    Article  PubMed  Google Scholar 

  20. Cocaine and opiates found in Caminiti’s body. November 1, 2004, ESPN.com.

    Google Scholar 

  21. Corrigan B. DHEA and sport. Clin J Sport Med. 2002;12:236–241.

    Article  PubMed  Google Scholar 

  22. Holden C. Interest grows in anti-aging drug. Science. 1995;269:33.

    Google Scholar 

  23. Di Pasquale MG. Dehydroepitestosterone (DHEA). Drugs Sport. 1994;2:2–3.

    Google Scholar 

  24. Issajenko A. Running Risks. Macmillan, Canada. 1990:146.

    Google Scholar 

  25. Deyssig R. Frisch H. Blum WF, et al. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinol. 1993;128:313–318.

    PubMed  CAS  Google Scholar 

  26. Bidlingmaier M, Wu Z, Strasburger CJ. Test method: GH. Bailliere’s Clin Endocrinol Metab. 2000;14:99–109.

    CAS  Google Scholar 

  27. Dean H. Does exogenous growth hormone improve athletic performance? Clin J Sport Med. 2002;12:250–253.

    Article  PubMed  Google Scholar 

  28. Rogol A. Sex steroid and growth hormone supplementation to enhance performance in adolescent athletes. Curr Opin Pediatr. 2000;12:382–387.

    Article  PubMed  CAS  Google Scholar 

  29. Colao A, Marzullo P, Di Somma C, et al. Growth hormone and the heart. Clin Endocrinol. 2001;54:137–154.

    Article  CAS  Google Scholar 

  30. Audran M, Gareau R, Matecki S, et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sport Exerc. 1999;31:639–645.

    Article  CAS  Google Scholar 

  31. Vergouwen PC, Collee T, Marx JJ. Haematocrit in elite athletes. Int J Sports Med. 1999;20:538–541.

    Article  PubMed  CAS  Google Scholar 

  32. Noakes TD. Tainted glory. Doping and athletic performance. N Engl J Med. 2004;151:847–849.

    Article  Google Scholar 

  33. World Anti-Doping Agency. The World Anti-Doping Code – The 2009 prohibited list, International Standard. Lausanne: WADA; 2008. Web site http://www.wada-ama.org.

  34. George A. Central nervous system stimulants. Bailliere’s Clin Endocrinol Metab. 2000;14:79–88.

    CAS  Google Scholar 

  35. Cregler L. Substance abuse in sports: The impact of cocaine, alcohol, steroids, and other drugs on the heart. In: Williams RA, ed. The Athlete and Heart Disease: Diagnosis, Evaluation and Management. Philadelphia: Lippincott, Williams and Wilkins; 1999:131–153.

    Google Scholar 

  36. Billman GE. Cocaine: a review of its toxic actions on cardiac function. Crit Rev Toxicol. 1995;25:113–132.

    Article  PubMed  CAS  Google Scholar 

  37. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289:1537–1545.

    Article  PubMed  CAS  Google Scholar 

  38. Williams AD, Cribb PJ, Cooke MB, et al. The effect of ephedra and caffeine on maximal strength and power in resistance-trained athletes. J Strength Cond Res. 2008;22:464–470.

    Article  PubMed  Google Scholar 

  39. Malek MH, Housh TJ, Coburn JW, et al. Effects of eight weeks of caffeine supplementation and endurance training on aerobic fitness and body composition. J Strength Cond Res.2006;20(4):751–755.

    PubMed  Google Scholar 

  40. Pipe A, Ayotte C. Nutritional supplements and doping. Clin J Sport Med. 2002;12:245–249.

    Article  PubMed  Google Scholar 

  41. Clauson KA, Shields KM, McQueen CE, et al. Safety issues associated with commercially available energy drinks. J Am Pharm Assoc. 2008;48(3):e55–e63.

    Article  Google Scholar 

  42. Graham TE, Spriet LL. Caffeine and exercise performance. Sport Sci Exerc. 1996;9:1.

    Google Scholar 

  43. Australia New Zealand Food Authority. Report of the expert group on the safety aspects of dietary caffeine ANZFA, Canberra. 2000.

    Google Scholar 

  44. http://www.ncaa.org.

  45. Ellison RC, Singer MR, Moore LL. Current caffeine intake of young children; amount and sources. J Am Diet Assoc. 1995;95:802–803.

    Article  PubMed  CAS  Google Scholar 

  46. Morgan KJ, Stults VJ, Zabik ME. Amount and dietary sources of caffeine and saccharin intake by individuals 5–18 years. Regul Toxiol Pharmacol. 1982;2:296–307.

    Article  CAS  Google Scholar 

  47. Nawrot P, Jorden S, Eastwood J, Rostein J, Hugenholtz A, Feeley M. Effects of caffeine on human health Food Addit Contam 2003;20:1–30.

    Google Scholar 

  48. Frary CD, Johnson RK, Wang MQ. Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc. 2003;103:1326–1331.

    Article  Google Scholar 

  49. Santa Maria A, Lopez A, Diaz M, et al. Evaluation of toxicity of guarana with invitro bioassays. Ecotoxicol Environ Saf. 1998;39:164–167.

    Article  PubMed  CAS  Google Scholar 

Suggested Web sites

Download references

Author information

Authors and Affiliations

  1. Section of Academic Pediatrics, Section of Orthopedic Surgery and Rehabilitation Medicine, Director of Primary Care Sports Medicine, The University of Chicago, 5841 S. Maryland Ave., MC 6082, Chicago, USA

    Holly J. Benjamin (Associate Professor of Pediatrics and Surgery)

Authors
  1. Holly J. Benjamin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph A. Congeni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Holly J. Benjamin .

Editor information

Editors and Affiliations

  1. Sports Cardiology Consultants, LLC, Chicago, 60654, Illinois, USA

    Christine E. Lawless

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Benjamin, H.J., Congeni, J.A. (2011). Cardiac Effects of Ergogenic Aides and Supplements. In: Lawless, C. (eds) Sports Cardiology Essentials. Springer, New York, NY. https://doi.org/10.1007/978-0-387-92775-6_20

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-92775-6_20

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-92774-9

  • Online ISBN: 978-0-387-92775-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation